At MSK, dedicated to improving cancer immunotherapy. Pondering resistance mechanisms, chronic inflammation, unexpected roles of interferon. Views my own.
New York, NY
Joined July 2017
- Tweets525
- Following326
- Followers1.6K
- Likes597
Pinned Tweet
Summary of our paper scim.ag/7p1 on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a bench-to-bedside journey to understand opposing roles of IFN in IO. Wonderful team w @EJohnWherry @divijmathew Caitlin Foley @MMarmarelis @Jbauml et al! 1/13
Andy Minn retweeted
Researchers at MSK continue to build upon early ideas in cancer research, breaking new ground and driving the field now known as "#immunotherapy" forward.
Today, one specific type of immunotherapy —therapeutic #cancervaccines — has taken center stage. Unlike traditional vaccines, which prevent disease, a cancer vaccine would actually treat the disease.
The concept is audacious. It is challenging. And it is also achievable, thanks to new technology and more support for researchers in the lab and the clinic.
Learn more from some of the MSK experts in this field, including Dr. David Scheinberg, @TheVinodLab, Dr. @bengrbm, and @EileenMOReilly: bit.ly/45s4YgZ
Congrats @NancyZh60672287 and @KSusztak for this amazing work showing a path toward more effective and insightful single cell diagnosis and discovery from patient samples!
Hey we are in the post-atlasing era — time for single cell research to translate into the clinic! How? Try CellSpectra. See this thread by the amazing @KSusztak:
Congrats, Chris and team! A really fascinating auto regulatory circuit. A great example of how unraveling the complexities of unexpected modulatory pathways could be the key to better immunotherapies.
🚨Today, in @NatureCancer, we show that CAR-T cells and CAR-NK cells contain the seeds of their own self-destruction. Disruption of a FAS-L/FAS circuit enhances CAR potency against liquid and solid cancers. rdcu.be/exjEy @MSKCancerCenter @parkerici @MSK_DeptOfMed
Congrats Aaron and team! The biological implications and the translational insight uncovered is fascinating. Discovery that some patients might naturally synthesize biologics that may improve immunotherapy, including blocking antibodies to type I IFN? Wow 🤯
T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too?
That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below
nature.com/articles/s41586-0…
Andy Minn retweeted
Excited to share our latest work out now in print @Nature! Lead by @almudena_Chaves and @ScottMillman_MD, we uncover how metabolic rewiring via OGDH controls tissue regeneration and stem cell fate in the intestine 🚀🚨 bit.ly/44oaOiW
This study describes one of the most amazing IFN-stimulated genes (ISGs) I have ever learned about!! Congrats @megclarks, Jorge Henao Mejia, and team! Your work is amazing. Thanks also to @TheMarkFdn for supporting this project as part of the Mark Foundation Center at Penn.
Thrilled to share our paper on how mitochondrial complex IV remodeling can modulate TAM functions and promote anti-tumor immunity! with @ksimeono, @MFMich1, @Notorious_MHC, @rakez_krish, @delafuentelab, @andyjminn, @JHMLab and those not on X! Out now in @ImmunityCP 🎉
Andy Minn retweeted
"But I am blown away by how much we have learned about Alzheimer’s over the last couple of years."—@BillGates
statnews.com/2025/06/17/bill…
"This is the moment to spend more money on research, not less."
Agree 💯
erictopol.substack.com/p/pre…
erictopol.substack.com/p/the…
Andy Minn retweeted
When the hardest cancers go unsolved, @xrtcell, MD (@StanfordMed), gets to work. The PICI Investigator is a recipient of the 2025 CRI Lloyd J. Old STAR Award from @CancerResearch—recognizing investigators who take on cancer’s toughest questions.
Dr. Kalbasi’s lab is reshaping cell therapy by engineering T cells with synthetic cytokine receptors, delivering powerful, targeted signals without toxic conditioning chemo (@Nature).
Now leading a pan-California IL-13Rα2 CAR-T trial for melanoma and rare solid tumors, Dr. Kalbasi is translating science into new hope for patients who need it most.
PICI is proud to support boundary-breaking research.
cancerresearch.org/media-roo…
#CancerImmunotherapy #CancerResearch
Andy Minn retweeted
We previously showed that IFNg is required for CAR-T efficacy in solid tumors, but is it always good? Here, we show that IFNg limits CD28 CAR-T cells and that protection from this signal drives greater antitumor activity and durability. Enjoy!
science.org/doi/10.1126/scit…
Andy Minn retweeted
Powerful piece on the dominance of NIH-funded science and its role in drug discovery. Cutting the NIH budget puts all the U.S. has built at risk. We urge
@RFKJr_Official & @NIHDirector_Jay to champion U.S. science and defend NIH funding statnews.com/2025/06/06/us-u… via @statnews
Andy Minn retweeted
🙌🎉🍾Celebrating Fei and his recently accepted paper in @NatureCancer! Grateful to all of our collaborators, co-authors, and excellent peer reviewers @NathanSinghLab, #SaarGill, and @JoshuaBrodyMD. Stay tuned for the final manuscript! @MSKCancerCenter #Tcellpower #NKcellpower
Congrats @themis_brown and team on this remarkable work! Some much welcomed good news. It’s exciting imagining the far-reaching significance to these findings — the power and consequence of “basic research” to understand how things work.
Excited to share our study describing a role for a subset of Thetis cells, TC IV, in tolerance to food antigens. A team effort led by Vanja Cabric and @YollandaPariso1 🧵 1/ science.org/doi/10.1126/scie…
Andy Minn retweeted
Please join us in celebrating the 2025 Pershing Square Sohn Cancer Prize winners! This year’s six scientists have been selected for their bold ideas and potential to transform cancer research. The winners are: pershingsquarephilanthropies…
Andy Minn retweeted
Yet more brilliance from @themis_brown - its been a joy to have a front-row seat watching her group essentially rewrite the textbook on early life immunity. Kudos to one of the best scientists and human beings that I am fortuate to know!
science.org/doi/10.1126/scie…
Looking fwd, I am honored for this privilege of returning to MSK, working w immense talent to advance their mission of ending cancer. Looking back, I am indebted to Penn, all my colleagues, and to the organizations supporting the research of all who tirelessly share this mission.
We're excited to share that Dr. Andy Minn will return to MSK as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.
This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with Dr. Joan Massagué, Director of the Sloan Kettering Institute (SKI), and his residency in the Department of Radiation Oncology, both at MSK, in 2003 and 2005 respectively.
Learn more about Dr. Minn: bit.ly/3YLjxZi
Andy Minn retweeted
”If I get an award, I have an opportunity to thank people. I also thank the people who tried to make my life miserable because they made me work harder and become more resilient.”
Next week, our podcast returns with conversations featuring our 2024 laureates.
In the meantime, have a listen to one of our favourite episodes from last season with 2023 medicine laureate Katalin Karikó: bit.ly/3yQkJQN
ALT Official Nobel Prize portrait of Katalin Karikó. Next to the image is a burgundy text box with the quote: "I also thank the people who tried to make my life miserable because they made me work harder."
Very neat work showing how chronic inflammation could alter the immune contexture of the tumor (eg T cell function) by impacting the tumor draining lymph nodes. A lot of implications! Congrats @SantoshVardhana and team.
Part 2 of our combined efforts with @SohrabShah and @VStrongMD to understand immune evasion in gastric cancer describes the work in this preprint, led by @GreedyApple and Emily Stroobant in a brilliant collaboration: biorxiv.org/content/10.1101/…
Andy Minn retweeted
We’re proud to see several members of our community named to @theNASciences! Congratulations to ASPIRE Awardee Ali Shilatifard, Mark Foundation Center for Lineage Plasticity PI Corey Abate-Shen, and Scientific Advisory Committee member @EJohnWherry! 🎉
themarkfoundation.org/blog/t…
Andy Minn retweeted
🚨Today in @CellCellPress, we show that RNA splicing factor mutations in myeloid cancers generate splicing-derived public neoantigens targetable by #TCR tx. Amazing collaboration co-led by @AbdelWahablab, @bradleybio, and @KlebanoffLab. #Tcellpower
cell.com/cell/fulltext/S0092…
Andy Minn retweeted
📢The Mark Foundation is hiring! 📢
Join us as a Scientific Director or Grants & Data Operations Coordinator and help us accelerate cancer research. #ScienceJobs #NonprofitJobs
Learn more: themarkfoundation.org/career…
